Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia
- 247 Downloads
Compliance with ethical standards
The only funds used were provided by the authors’ institutions.
Conflict of interest
AI has received speaker honoraria from Bristol Myers Squibb (BMS), Novartis, Pfizer, and Incyte. All remaining authors have declared no conflicts of interest.